Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 35 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Aravantinos, Gerasimos [Clear All Filters]
Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative..
Oncotarget. 11(1), 1-14.
(2020). Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer..
Cancer Genomics Proteomics. 17(2), 181-193.
(2020). Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab..
ESMO Open. 4(2), e000441.
(2019). Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab..
Transl Oncol. 12(5), 739-748.
(2019). AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer..
Clin Colorectal Cancer. 17(4), e631-e637.
(2018). Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials..
Clin Breast Cancer. 18(1), 53-62.e3.
(2018). Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer..
Oncotarget. 9(86), 35623-35638.
(2018). Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group..
J Transl Med. 15(1), 30.
(2017). Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers..
Cancer Genomics Proteomics. 14(3), 181-195.
(2017). Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer..
Anticancer Res. 37(5), 2323-2334.
(2017). Protein expression patterns of cell cycle regulators in operable breast cancer..
PLoS One. 12(8), e0180489.
(2017). Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study..
PLoS One. 11(10), e0164013.
(2016). Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes..
Breast Cancer Res Treat. 158(2), 307-21.
(2016). Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer..
Anticancer Res. 36(5), 2365-78.
(2016). Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia..
Mol Clin Oncol. 4(2), 211-220.
(2016). MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer..
J Transl Med. 14(1), 136.
(2016).
(2016).
(2016). Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study..
J Transl Med. 13, 171.
(2015). Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial..
PLoS One. 10(5), e0124612.
(2015). Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study..
Histol Histopathol. 30(9), 1129-41.
(2015). PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients..
Cancer Chemother Pharmacol. 75(6), 1289-301.
(2015).
(2015). Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17..
PLoS One. 9(8), e103707.
(2014). KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study..
BMJ Open. 4(5), e004652.
(2014).